In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon: Can Spec Pharma do R&D?

Executive Summary

Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.

You may also be interested in...



Reformulation has Ruled in Neurology Dealmaking--Until Now

The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.

Shire: Remodeling Specialty Pharma

As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.

Shire: Remodeling Specialty Pharma

As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel